Wooridul Huebrain Limited (118000.KS)
KRW 298.0
(-1.32%)
KRW 298.0
(-1.32%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -14.54 Billion KRW | 82.32% |
| 2022 | -82.22 Billion KRW | -1162.29% |
| 2021 | 7.73 Billion KRW | -31.22% |
| 2020 | 11.25 Billion KRW | 378.33% |
| 2019 | -4.04 Billion KRW | 66.43% |
| 2018 | -12.04 Billion KRW | -314.01% |
| 2017 | -2.9 Billion KRW | 66.26% |
| 2016 | -8.62 Billion KRW | -13.52% |
| 2015 | -7.59 Billion KRW | 14.16% |
| 2014 | -8.84 Billion KRW | -93.89% |
| 2013 | -4.56 Billion KRW | 28.78% |
| 2012 | -6.4 Billion KRW | 48.86% |
| 2011 | -12.52 Billion KRW | -357.55% |
| 2010 | -2.73 Billion KRW | -896.0% |
| 2009 | 343.97 Million KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 13.6 Billion KRW | 214.49% |
| 2024 Q2 | -1.71 Billion KRW | -112.64% |
| 2023 FY | -14.54 Billion KRW | 82.32% |
| 2023 Q2 | 3.32 Billion KRW | 283.35% |
| 2023 Q1 | -1.81 Billion KRW | 92.88% |
| 2023 Q4 | -11.88 Billion KRW | -117.88% |
| 2023 Q3 | -5.45 Billion KRW | -263.96% |
| 2022 FY | -82.22 Billion KRW | -1162.29% |
| 2022 Q2 | -15.8 Billion KRW | -171.45% |
| 2022 Q1 | -5.82 Billion KRW | -354.46% |
| 2022 Q3 | -10.46 Billion KRW | 33.77% |
| 2022 Q4 | -25.49 Billion KRW | -143.58% |
| 2021 Q3 | -4.17 Billion KRW | -140.0% |
| 2021 Q1 | -3.37 Billion KRW | -153.77% |
| 2021 FY | 7.73 Billion KRW | -31.22% |
| 2021 Q2 | 10.43 Billion KRW | 408.8% |
| 2021 Q4 | 2.28 Billion KRW | 154.82% |
| 2020 Q4 | 6.28 Billion KRW | 99.91% |
| 2020 Q2 | 3.43 Billion KRW | 313.35% |
| 2020 Q1 | -1.6 Billion KRW | -288.69% |
| 2020 FY | 11.25 Billion KRW | 378.33% |
| 2020 Q3 | 3.14 Billion KRW | -8.35% |
| 2019 Q1 | -2.14 Billion KRW | 68.23% |
| 2019 FY | -4.04 Billion KRW | 66.43% |
| 2019 Q3 | -1.64 Billion KRW | 11.61% |
| 2019 Q4 | 852.2 Million KRW | 151.74% |
| 2019 Q2 | -1.86 Billion KRW | 13.11% |
| 2018 Q1 | -1.7 Billion KRW | -455.29% |
| 2018 Q4 | -6.75 Billion KRW | -334.23% |
| 2018 Q3 | -1.55 Billion KRW | 23.47% |
| 2018 FY | -12.04 Billion KRW | -314.01% |
| 2018 Q2 | -2.03 Billion KRW | -19.12% |
| 2017 FY | -2.9 Billion KRW | 66.26% |
| 2017 Q2 | -2.22 Billion KRW | -127.69% |
| 2017 Q3 | -2.28 Billion KRW | -3.06% |
| 2017 Q4 | 480 Million KRW | 120.97% |
| 2017 Q1 | -975.51 Million KRW | 79.05% |
| 2016 Q1 | -1.15 Billion KRW | 20.02% |
| 2016 FY | -8.62 Billion KRW | -13.52% |
| 2016 Q4 | -4.65 Billion KRW | -253.47% |
| 2016 Q3 | -1.31 Billion KRW | 11.57% |
| 2016 Q2 | -1.48 Billion KRW | -28.82% |
| 2015 Q4 | -1.44 Billion KRW | 34.63% |
| 2015 Q3 | -2.21 Billion KRW | -1.9% |
| 2015 FY | -7.59 Billion KRW | 14.16% |
| 2015 Q1 | -1.76 Billion KRW | 66.99% |
| 2015 Q2 | -2.17 Billion KRW | -22.96% |
| 2014 Q1 | -1.23 Billion KRW | 29.85% |
| 2014 FY | -8.84 Billion KRW | -93.89% |
| 2014 Q4 | -5.34 Billion KRW | -405.28% |
| 2014 Q3 | -1.05 Billion KRW | 12.14% |
| 2014 Q2 | -1.2 Billion KRW | 2.45% |
| 2013 Q1 | -769.12 Million KRW | 8.87% |
| 2013 Q3 | -1.15 Billion KRW | -32.43% |
| 2013 FY | -4.56 Billion KRW | 28.78% |
| 2013 Q2 | -874.62 Million KRW | -13.72% |
| 2013 Q4 | -1.76 Billion KRW | -52.0% |
| 2012 FY | -6.4 Billion KRW | 48.86% |
| 2012 Q2 | -3.33 Billion KRW | -121.31% |
| 2012 Q1 | -1.5 Billion KRW | 73.15% |
| 2012 Q4 | -843.94 Million KRW | -16.71% |
| 2012 Q3 | -723.13 Million KRW | 78.3% |
| 2011 Q2 | -4.69 Billion KRW | -574.26% |
| 2011 Q4 | -5.6 Billion KRW | -248.78% |
| 2011 FY | -12.52 Billion KRW | -357.55% |
| 2011 Q1 | -696.22 Million KRW | 52.41% |
| 2011 Q3 | -1.6 Billion KRW | 65.74% |
| 2010 Q3 | -1.61 Billion KRW | 2.23% |
| 2010 Q2 | -1.64 Billion KRW | -181.84% |
| 2010 Q1 | 2.01 Billion KRW | 0.0% |
| 2010 FY | -2.73 Billion KRW | -896.0% |
| 2010 Q4 | -1.46 Billion KRW | 9.26% |
| 2009 FY | 343.97 Million KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Daewoong Co., Ltd. | 152.66 Billion KRW | 109.524% |
| PharmGen Science, Inc. | 5.72 Billion KRW | 353.879% |